Medical Management of Endometriosis: Novel Targets and Approaches towards the Development of Future Treatment Regimes

Warren B Nothnick, Thomas D'Hooghe, Thomas D’Hooghe, Thomas M D'Hooghe
Gynecologic and obstetric investigation · 2003 · vol. 55(4) , pp. 189–198 · doi:10.1159/000072073 · PMID:12904691 · W2114388502
review OA: closed CC0 ⤵ 36 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-07 ⓘ

This review discusses the limitations of current hypoestrogenic endometriosis treatments and highlights tumor necrosis factor inhibitors as promising alternative therapeutic targets for future treatment regimes.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Endometriosis remains an enigmatic disease in women of reproductive age. Current treatment regimes used to manage the disease are primarily designed to induce a hypoestrogenic state which leads to a reduction in disease and associated symptoms. While these regimes have been used with great success, there are still drawbacks and limitations to these types of therapies. In this review, we address the shortcomings of current drugs used to medically manage endometriosis and offer potential target areas which may be attractive alternatives to current therapies. Emphasis is placed upon the promising research using tumor necrosis factor inhibitors in this context. Further, we discuss the advantages of such therapies and offer experimental approaches towards the development and testing of these regimes.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Adjuvants, Immunologic Adjuvants, Immunologic Anti-Inflammatory Agents, Non-Steroidal Anti-Inflammatory Agents, Non-Steroidal Aromatase Inhibitors Endometriosis Female Humans Matrix Metalloproteinase Inhibitors Progesterone Progesterone Tumor Necrosis Factor-alpha Tumor Necrosis Factor-alpha

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (95)

Cited by (36)

Source provenance

europepmc
last seen: 2026-06-13T06:22:48.782012+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:12:50.257867+00:00
unpaywall
last seen: 2026-06-13T06:42:57.164913+00:00
License: CC0 · commercial use OK